Positron emission tomography using a newly-developed PET probe: [18F] fluoroacetate (FACE) - clinical patient study -

Positron emission tomography using a newly-developed PET probe: [18F] fluoroacetate (FACE) - clinical patient study - - FACE clinical patient study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008837

Enrollment

200

Registered

2012-09-03

Start date

2012-09-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with cancers or with neurological diseases

Interventions

Injection dose 5.0MBq per kg, maximum dose 370MBq. Dynamic or static data acquisition up to 2hr. Venous blood sampling (10mL).

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with cancers or with neurological diseases

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Dynamic dat acquisition (0 min after the intravenous injection up to 2hr after injection) using PET scanner. Or static data acquisition (20 min 1hr after injection).	—

Secondary

Measure	Time frame
Data obtained at studies with cancer patients can be used as control for neurological studies. Data obtained at studies with neurological patients can be used as control for studies with cancers.	—

Countries

Japan

Contacts

Public ContactShigenori Shimomura

Shiga Medical Center Research Institute Division of Imaging Research

kenkyu@res.med.shiga-pref.jp077-582-6034

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026